相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients
Salvador E. Cabrera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Jackson K. Mukonzo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Genetic Susceptibility of Lung Cancer Associated With Common Variants in the 3′ Untranslated Regions of the Adenosine Triphosphate-Binding Cassette B1 (ABCB1) and ABCC1 Candidate Transporter Genes for Carcinogen Export
Haijian Wang et al.
CANCER (2009)
Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites
Andrea S. Blevins-Primeau et al.
CANCER RESEARCH (2009)
Quantification of 8 HIV-Protease Inhibitors and 2 Nonnucleoside Reverse Transcriptase Inhibitors by Ultra-Performance Liquid Chromatography with Diode Array Detection
Laure Elens et al.
CLINICAL CHEMISTRY (2009)
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
Anne-Sophie Belanger et al.
DRUG METABOLISM AND DISPOSITION (2009)
Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells
L. Elens et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
CYP2B6 Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port-au-Prince, Haiti
Paul Leger et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans
David W. Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier
Sandrine Dauchy et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene
Federico Innocenti et al.
PHARMACOGENETICS AND GENOMICS (2008)
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26
Hiroyuki Gatanaga et al.
CLINICAL INFECTIOUS DISEASES (2007)
Polymorphic CYP2B6:: molecular mechanisms and emerging clinical significance
Ulrich M. Zanger et al.
PHARMACOGENOMICS (2007)
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
Zeruesenay Desta et al.
PHARMACOGENOMICS (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects
G. W. Hogeland et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study
Alison A. Motsinger et al.
PHARMACOGENETICS AND GENOMICS (2006)
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Sara Colombo et al.
THERAPEUTIC DRUG MONITORING (2006)
Clinical implications of CYP3A polymorphisms
Leszek Wojnowski et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study
DW Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
DB Clifford et al.
ANNALS OF INTERNAL MEDICINE (2005)
Three haplotypes associated with CYP2A6 phenotypes in Caucasians
M Haberl et al.
PHARMACOGENETICS AND GENOMICS (2005)
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
S Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2005)
An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children
A Saitoh et al.
AIDS (2005)
Efavirenz intoxication due to slow hepatic metabolism
B Hasse et al.
CLINICAL INFECTIOUS DISEASES (2005)
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
K Tsuchiya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance
C Marzolini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver
M Furukawa et al.
CANCER SCIENCE (2004)
Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy
T Hulgan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients
M Nasi et al.
AIDS (2003)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response
ZL Brumme et al.
AIDS (2003)
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection
DW Haas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
C Csajka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
J Fellay et al.
LANCET (2002)
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
M Hitzl et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
分享论文
